Connelly, Kathryn http://orcid.org/0000-0003-1332-5050
Eades, Laura E.
Koelmeyer, Rachel
Ayton, Darshini
Golder, Vera
Kandane-Rathnayake, Rangi
Gregory, Kate
Brunner, Hermine http://orcid.org/0000-0001-9478-2987
Burke, Laurie
Arnaud, Laurent http://orcid.org/0000-0002-8077-8394
Askanase, Anca
Aranow, Cynthia
Vital, Ed http://orcid.org/0000-0003-1637-4755
Pons-Estel, Guillermo
Dantata, Khadija
Andersen, Jeanette http://orcid.org/0000-0001-8848-9039
Cornet, Alain
Buie, Joy
Sun, Ying
Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Simon, Lee
Lahoud, Youmna http://orcid.org/0000-0002-5677-3665
Friedman, Alan
Kalunian, Kenneth
Zuraw, Qing
Werth, Victoria
Garces, Sandra
Morand, Eric F. http://orcid.org/0000-0002-9507-3338
Sorrentino, Alessandro
Stevens, Anna
Barbey, Catherine
Karis, Elaine
Morand, Eric
Noss, Erika
MD Smith, Eve
Stojan, George
Teres, Jorge Ross
Maller, Justine
Hojnik, Maya
Delev, Nikolay
Eades, Laura
Dall’Era, Maria
Marquis, Patrick
Furie, Richard
van Vollenhoven, Ronald
Coulom, Tim
Sibley, Cailin
Stach, Christian
Vazquez-Mateo, Cristina
Zollars, Eric
Guay, Heath
Al-Mossawi, Hussein
Merrill, Joan
Terres, Jorge Ross
Costenbader, Karen
Silk, Maria
Mosca, Marta
Bush, Nicki
Banerjee, Subhashis
Sornasse, Thierry
Rubio, Blanca
Tremarias, Dalila
Kalla, Dalilah
Carrizo, Gonzalo Tobar
Adisa, Imasha
Nagamori, Shiori
Komati, Sibongile
Scoggins, Stephanie
Gydesen, Susanne Udengaard
Grimes, Toni
Haroun, Vinita
Karakikla-Mitsa, Zoe
Eldred, Ann
Fedriz, Bianca
Lindholm, Catharine
Lupton, Charlotte
Grasela, Dennis
Thomas, Erik
Juarez, Maria
Kumar, Nitin
Guenther, Oliver
Pomponi, Samantha
Roy, Sanjeev
Kafka, Shelly
Morel, Thomas
Pincus, Yulia
,
,
,
,
,
,
Article History
Accepted: 9 June 2023
First Online: 11 July 2023
Competing interests
: H.B. has received grants from Pfizer and fees from Novartis, Pfizer and Roche. The Cincinnati Children’s Hospital where H.B., the PRCSG Chairperson, works as a full-time employee, has received contributions for consultation from the following industries in the past 2 years: AbbVie, AstraZeneca-Medimmune, Biogen, Boehringer, Bristol-Myers Squibb, Celgene, Cerocor, Eli Lilly, F. Hoffmann-La Roche, Horizon, Idorsia, Janssen, Merck, Novartis and Sanofi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment to third parties. L.A. has received grants from GlaxoSmithKline and fees from AbbVie, Alexion, Amgen, AstraZeneca, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Grifols, Janssen, LFB, Medac, Novartis, Pfizer, Chugai, Sêmeia and UCB. A.A. has received fees from AbbVie/Abbott, AstraZeneca, Amgen, Aurinia, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Idorsia, Janssen, Pfizer and UCB. E.V. has received fees from Aurinia, Eli Lilly, Novartis, Pfizer, Roche and UCB. G.P.-E. has received fees from GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanofi and Werfen/Inova. Y.T. has received grants from AbbVie, Asahi-Kasei, Boehringer-Ingelheim, Chugai, Daiichi-Sankyo, Eisai and Takeda, and fees from AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Mitsubishi-Tanabe and Pfizer. L.S. has received fees from Ampio, Amzell, Applied Biosystems, Aptinyx, AstraZeneca, Aura, Aurinia, Bexson, Biosplice, Boehringer-Ingelheim, Bone Med, Bone Therapeutics, Bristol-Myers Squibb, Cancer Prevention, Cerebral Therapeutics, Chemocentryx, Chemomab, Diffusion Bio, Direct, Eli Lilly, Elorac, EMD Serono, Enalare, Eupraxia, Foundry Therapeutics, Galapagos, Galvani, Gilead, GlaxoSmithKline, Histogen, Horizon Therapeutics, Idera, Ingel, Intravital, Kaniska, Kiel Labs, Kyoto, Mesoblast, Minerva, Mpathix, Neema, Neumentum, Pfizer, PPD, Priovant, Protalix, Regenosine, Rigel, Roivant, Samus, Sana, SpineThera, StageBio, Theraly, TLC, Transcode, Unity, Urica, Viridian and Xalud. Y.L. is an employee of Biogen and owns shares in Biogen stock. A.F. is an employee of AbbVie and owns shares in AbbVie stock. K.K. has received fees from AbbVie/Abbott, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Eli Lilly, Equillium, Genentech, Gilead, Janssen, Nektar, Pfizer, Roche, Sanford Consortium and Viela. Q.Z. is an employee of Janssen. V.W. has received fees from AbbVie/Abbott, Amgen, AnaptysBio, Argenx, AstraZeneca, Biogen, Bristol Myers Squibb, Celgene, Corbus, CSL Behring, Eli Lilly, EMD Serono, Galderma, Genentech, Gilead, GlaxoSmithKline, Horizon Therapeutics, Janssen, Merck/MSD, Nektar, Novartis, Octapharma, Pfizer, Principia, Regeneron, Resolve, Rome Pharmaceuticals, Sanofi, Syntimmune and Viela. S. Garces is an employee of Amgen. E.M. has received grants from AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline, Janssen and UCB, and fees from Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Capella, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline, Janssen, Neovacs, Novartis, Sanofi, Servier, UCB, Wolf and Zenas. All other authors declare no competing interests.
Free to read: This content has been made available to all.